Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Therapy
Risk of recurrence is reduced in women treated with letrozole for breast cancer
February 16th, 2006
The risk of recurrent disease is reduced in women treated with letrozole for early breast cancer. Investigators in Switzerland report, "The aromatase inhibitor letrozole is a more effective treatment for metastatic breast cancer and more effective in the neoadjuvant setting than tamoxifen. We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women." B. Thurlimann and colleagues of the Cantonal Hospital of St. Gallen stated, "The Breast International Group (BIG) 1-98 study is a randomized, phase 3, double-blind trial that compared five years of treatment with various adjuvant...
Source: Women's Health Weekly (2006-02-16)
|
